Gilead and Kite to present data from cell therapy research at 25th EHA Virtual Congress

Gilead Sciences, Inc. and Kite, a Gilead Company, are pleased to support the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress, taking place 11–21 June 2020.

The EHA Annual Congress provides a key platform for hematologists from across Europe and around the world to increase their knowledge of evidence-based approaches for hematologic diseases, access the latest results on clinical and translational research in hematologic disorders and further understand emerging innovative techniques, diagnostic tools and risk-assessment strategies in hematology and its subspecialties.

Gilead and Kite will be presenting scientific and real-world data from their cell therapy research programs to attending healthcare professionals.

We are pleased to be supporting the virtual edition of the EHA Congress 2020 and look forward to engaging, collaborating and sharing new data with hematologists throughout Europe and around the world. Our presentations at this invaluable international meeting form part of our ongoing commitment to realizing the full potential of cell therapy through continued research in advanced blood cancers.”

Dick Sundh, Vice President, Head of Europe, Kite

Presentations at the congress will include:

Presentation Number and Date/Time (CEST) Abstract Title
Abstract #EP1259  
(e-poster)
Friday 12 June 2020
08:00 – 23:59  
Retreatment of patients with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1 – F. Locke, Moffitt Cancer Center, Tampa, FL, USA
Abstract #EP1763
(e-poster)
Friday 12 June 2020
08:00 – 23:59
Axicabtagene ciloleucel for the management of patients with diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma: an economic evaluation for Spain – M. Presa, Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain
Abstract #EP1731  
(e-poster)
Friday 12 June 2020
08:00 – 23:59
Cost effectiveness of axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for adult patients with relapsed or refractory large B-cell lymphoma (RR LBCL) in the US – J. Thornton Snider, Kite, a Gilead Company, Santa Monica, CA, USA
Abstract #S144
(oral)
Saturday 13 June 2020
08:00 – 23:59
The first-in-class anti-CD47 antibody magrolimab combined with azacitidine is well-tolerated and effective in AML patients: Phase 1b results – N. Daver, MD Anderson Cancer Center, Houston, TX, USA
Abstract #S287
(oral)
Sunday 14 June 2020
08:00 – 23:59
Interim analysis of ZUMA-5: A Phase 2 study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL) – C.A. Jacobson, Dana-Farber Cancer Institute, Boston, MA, USA
Abstract #S187
(oral)
Sunday 14 June
2020 08:00 – 23:59
The first-in-class anti-CD47 antibody magrolimab combined with azacitidine is well-tolerated and effective in MDS patients: Phase 1b results – D. Sallman, Moffitt Cancer Center, Tampa, FL, USA

The following experts from Kite will be available for comments:

  • Dick Sundh, Vice President, Head of Europe, Kite
  • Bethany Dudek, Executive Director, Quality Head Europe, Kite
  • Anne Kerber, Vice President, Head Clinical Development EU, Kite

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Gilead Sciences, Inc.. (2020, June 10). Gilead and Kite to present data from cell therapy research at 25th EHA Virtual Congress. News-Medical. Retrieved on September 25, 2020 from https://www.news-medical.net/news/20200610/Gilead-and-Kite-to-present-data-from-cell-therapy-research-at-25th-EHA-Virtual-Congress.aspx.

  • MLA

    Gilead Sciences, Inc.. "Gilead and Kite to present data from cell therapy research at 25th EHA Virtual Congress". News-Medical. 25 September 2020. <https://www.news-medical.net/news/20200610/Gilead-and-Kite-to-present-data-from-cell-therapy-research-at-25th-EHA-Virtual-Congress.aspx>.

  • Chicago

    Gilead Sciences, Inc.. "Gilead and Kite to present data from cell therapy research at 25th EHA Virtual Congress". News-Medical. https://www.news-medical.net/news/20200610/Gilead-and-Kite-to-present-data-from-cell-therapy-research-at-25th-EHA-Virtual-Congress.aspx. (accessed September 25, 2020).

  • Harvard

    Gilead Sciences, Inc.. 2020. Gilead and Kite to present data from cell therapy research at 25th EHA Virtual Congress. News-Medical, viewed 25 September 2020, https://www.news-medical.net/news/20200610/Gilead-and-Kite-to-present-data-from-cell-therapy-research-at-25th-EHA-Virtual-Congress.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.